ArticleBMC infectious diseases2025
Prevalence of antibodies against rubella virus, cytomegalovirus, hepatitis b, and Toxoplasma gondii in women of reproductive age prior to conception in Iran.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasma gondii (TOX), Rubella virus (RUV), Cytomegalovirus (CMV) and herpes simplex virus (HSV) are major TORCH pathogens that can cause serious congenital infections and adverse pregnancy outcomes if primary infection occurs during pregnancy. This cross-sectional study assessed the serological status of TORCH infections among 388 women of reproductive age prior to conception referred to a clinical laboratory in Tabriz, Iran, between April 2024 and April 2025. The objective was to determine the prevalence of IgG and IgM antibodies against Toxoplasma gondii, Rubella virus, CMV, and the presence of Hepatitis B surface antigen (HBsAg). Serum samples were analyzed using a chemiluminescence immunoassay, and data were processed with SPSS software version 22. Results showed that IgG seropositivity for Toxoplasma gondii was 28.4% (95% CI: 23.7-33.5%), significantly increasing with age (p = 0.004), with the highest rate (40.2%, 95% CI: 31.5-49.4%) observed among women aged 36-45. Rubella IgG antibodies were detected in 95.6% (95% CI: 92.7-97.6%) of participants, with the highest prevalence (98.3%, 95% CI: 94.4-99.8%, p = 0.000) in the 26-35 age group. CMV IgG seropositivity was found in 99.7% (95% CI: 98.4-100%) of women, with no statistically significant differences across age groups. HBsAg was present in 1% (95% CI: 0.3-2.7%) of the participants, and although slightly higher in older women, the association with age was not statistically significant (p = 0.384). These findings highlight a high level of immunity against Rubella and CMV, moderate exposure to Toxoplasma gondii, and a low prevalence of active Hepatitis B infection. Routine TORCH screening in women of reproductive age is essential as part of preconception care to prevent congenital infections and associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.